ARTICLES BY WALTER COLASANTE

• What Risks Do Annuity Pricing Models Present To Cell & Gene Therapy Developers?

  5/9/2019

  Over the past four decades, and especially in recent years, progress in the development of cell and gene therapies has reached unprecedented levels. In gene therapy alone, between 1989 and 2015 there were more than 2,330 clinical research programs targeting almost 50 different indications.^1,2 As more cell and gene therapies reach commercial stage, industry insiders expect research in the sector to continue to expand in the coming years. For patients, clinicians, and health systems, new cell and gene therapies bring the promise of historic and transformative advances in the treatment of many serious diseases. 

• New Approaches To Market Access And Reimbursement For Gene And Cell Therapies

  9/6/2018

  Current reimbursement models in general do not accommodate many of the unique factors that are common among gene and cell therapies.

• Building New Business Models To Support Cell And Gene Therapy R&D

  7/5/2018

  Gene and cell therapy research has progressed despite the considerable challenges that require new approaches to the standard drug-development process and timeline. Here are some alternate development and financing models to consider.